Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.

Bagegni, Nusayba A; Davis, Andrew A; Clifton, Katherine K; Ademuyiwa, Foluso O

Bagegni, Nusayba A; Davis, Andrew A; Clifton, Katherine K; Ademuyiwa, Foluso O.

Afiliación

Bagegni NA; Division of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA.
Davis AA; Division of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA.
Clifton KK; Division of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA.
Ademuyiwa FO; Division of Oncology, Department of Medicine, Washington University in St Louis School of Medicine, St Louis, MO, 63110, USA.

Breast Cancer (Dove Med Press) ; 14: 113-123, 2022.

Article en En | MEDLINE | ID: mdl-35515356

Palabras clave

adjuvant; early-stage high-risk; immune biomarkers; neoadjuvant; pembrolizumab; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Tipo de estudio: Clinical_trials / Etiology_studies / Risk_factors_studies Idioma: En Revista: Breast Cancer (Dove Med Press) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google